- Home
- GLAD vs XERS Comparison
GLAD vs XERS Comparison
Compare GLAD & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLAD
- XERS
- Stock Information
- Founded
- GLAD 2001
- XERS 2005
- Country
- GLAD United States
- XERS United States
- Employees
- GLAD N/A
- XERS N/A
- Industry
- GLAD Finance/Investors Services
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- GLAD Finance
- XERS Health Care
- Exchange
- GLAD Nasdaq
- XERS Nasdaq
- Market Cap
- GLAD 571.4M
- XERS 628.7M
- IPO Year
- GLAD N/A
- XERS 2018
- Fundamental
- Price
- GLAD $26.53
- XERS $4.51
- Analyst Decision
- GLAD Hold
- XERS Strong Buy
- Analyst Count
- GLAD 1
- XERS 6
- Target Price
- GLAD $23.00
- XERS $6.25
- AVG Volume (30 Days)
- GLAD 80.8K
- XERS 2.2M
- Earning Date
- GLAD 08-06-2025
- XERS 08-07-2025
- Dividend Yield
- GLAD 8.97%
- XERS N/A
- EPS Growth
- GLAD 17.67
- XERS N/A
- EPS
- GLAD 3.93
- XERS N/A
- Revenue
- GLAD $92,932,000.00
- XERS $222,551,000.00
- Revenue This Year
- GLAD N/A
- XERS $35.03
- Revenue Next Year
- GLAD $12.10
- XERS $18.31
- P/E Ratio
- GLAD $6.76
- XERS N/A
- Revenue Growth
- GLAD N/A
- XERS 29.88
- 52 Week Low
- GLAD $21.40
- XERS $2.03
- 52 Week High
- GLAD $30.43
- XERS $6.07
- Technical
- Relative Strength Index (RSI)
- GLAD 50.08
- XERS 46.97
- Support Level
- GLAD $26.40
- XERS $4.30
- Resistance Level
- GLAD $27.04
- XERS $4.79
- Average True Range (ATR)
- GLAD 0.47
- XERS 0.23
- MACD
- GLAD -0.05
- XERS -0.01
- Stochastic Oscillator
- GLAD 23.19
- XERS 25.93
About GLAD Gladstone Capital Corporation
Gladstone Capital Corp is an externally managed, closed-end, non-diversified management investment company. Its investment objectives are to, achieve and grow current income by investing in debt securities of established businesses that would provide stable earnings and cash flow to pay expenses, make principal and interest payments on its outstanding indebtedness, and make distributions to stockholders that grow over time; and provide its stockholders with long-term capital appreciation in the value of its assets by investing in equity securities of established businesses that can grow over time to permit it to sell its equity investments for capital gains.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing's syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).